FICP President, Indian Diabetes, Research Foundation (IDRF), Chairman - Dr A Ramachandran’s Diabetes Hospitals, Chennai

This session explores the evolving paradigm of cardio-renal-metabolic care, highlighting how SGLT2 inhibitor and DPP-4 inhibitor combinations can improve outcomes in patients with type 2 diabetes and associated co-morbidities. It focuses on mechanisms, patient selection, real-world evidence, and practical strategies to achieve comprehensive heart, kidney, and metabolic protection in routine clinical practice.

Dr. A Ramachandran

1

-

-

-

Upcoming Sessions